MARKET

SYRS

SYRS

Syros Pharmaceut
NASDAQ
5.23
-0.61
-10.45%
Opening 14:21 03/28 EDT
OPEN
5.58
PREV CLOSE
5.84
HIGH
5.90
LOW
5.15
VOLUME
205.49K
TURNOVER
0
52 WEEK HIGH
8.17
52 WEEK LOW
2.090
MARKET CAP
138.35M
P/E (TTM)
-1.4578
1D
5D
1M
3M
1Y
5Y
SYRS Stock Earnings: Syros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
Syros Pharmaceuticals reported earnings per share of -$2.22. The company reported revenue of $386,000. This was 80.70% worse than the analyst estimate for revenue of $2.00 million. The company's revenue was also below the analyst estimates.
Investorplace · 1d ago
Syros Pharmaceuticals: Buy Rating on Strong Financials and High Potential of Tamibarotene Trials
TipRanks · 1d ago
Syros Pharma Shares Slide After 4Q Loss Widens
Syros Pharmaceuticals recorded a wider loss in the fourth quarter than analysts had been expecting. The stock was down 6.4% at $5.85 in early trading. Shares have now fallen by nearly a quarter year-to-date. The company recorded a loss of $64.4 million.
Dow Jones · 1d ago
Syros Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Syros Pharmaceuticals Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of $2.18 per share. Revenue fell 48.7% to $387.00 million from a year ago. The average analyst rating on the company's shares is "buy"
Reuters · 1d ago
Syros Pharmaceuticals GAAP EPS of -$2.18 misses by $1.04, revenue of $0.4M misses by $1.6M
Syros Pharmaceuticals GAAP EPS of -$2.18 misses by $1.04, revenue of $0.4M misses by £1.6M in Q4. The company says it has $139.5 million in cash and cash equivalents as of December 31, 2022.
Seeking Alpha · 1d ago
Syros Pharmaceuticals Q4 EPS $(2.22) Misses $(1.14) Estimate, Sales $386.00K Miss $2.00M Estimate
Syros Pharmaceuticals reported quarterly losses of $2.22 per share. The company missed the analyst consensus estimate by 94.74%. The company reported quarterly sales of $386.00 million which missed the estimate by 80.70 percent. Syros also reported a 151.19 percent increase in sales for the same period.
Benzinga · 1d ago
BRIEF-Syros Pharmaceuticals Q4 EPS USD -2.18
Reuters · 1d ago
Press Release: Syros Reports Fourth Quarter and -2-
Freedom to operate under third party intellectual property; obtain and maintain necessary regulatory approvals; manage competition; and raise the substantial additional capital needed to achieve its business objectives. Syros Pharmaceuticals, Inc. Also faces risks described under the caption "Risk Factors" in its annual report on Form 10-K for the year ended December 31, 2023. The company's assets and liabilities are included in the condensed consolidated financial statements.
Dow Jones · 1d ago
More
About SYRS
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. Its lead product candidates include Tamibarotene and SY-2101. Its Tamibarotene, is a selective retinoic acid receptor alpha (RARα), agonist RARA-positive patients with higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). Its SY-2101, is an oral form of arsenic trioxide (ATO) being developed for the treatment of acute promyelocytic leukemia (APL). The Company’s product candidate also includes SY-5609, which is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) which is being developed for patients with select solid tumors and in combination with gemcitabine and with gemcitabine plus nab-paclitaxel in patients with metastatic pancreatic cancer. It is also focused on the development for the treatment of multiple preclinical programs in oncology.

Webull offers Syros Pharmaceuticals Inc stock information, including NASDAQ: SYRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SYRS stock methods without spending real money on the virtual paper trading platform.